November 9-11, 2020 | Virtual Conference


Chad Landmon, J.D.

Axinn, Veltrop & Harkrider LLP

Chad Landmon is a partner at Axinn, Veltrop & Harkrider LLP, where he chairs the FDA and IP Practice Groups. Chad has nearly 20 years of experience in food and drug law and patent litigation and counseling. He has served as lead trial counsel in high stakes patent and FDA litigation throughout the United States, handling over 50 cases in numerous federal district and appellate courts, involving products with over $100 billion in sales. His practice involves client counseling and petitioning FDA and litigating issues relating to the Biologics Price Competition and Innovation Act (BPCIA), including the requirements for the demonstration of biosimilarity and the patent resolution provisions, and issues relating to the Hatch-Waxman Act, including marketing exclusivities, patent listing, certification and notification requirements, bioequivalence, labeling, and other issues. Chad’s practice also includes matters involving the intersection of the antitrust and patent laws, such as issues arising from the settlement of patent and FDA exclusivity disputes.

Skip to content